We previously reported that fucoidan, a dietary fiber purified from seaweed, inhibited IgE production by B cells in vitro. In this study, we examined the effect of fucoidan on IgE production in vivo. The OVA-induced increase of plasma IgE was significantly suppressed when fucoidan was intraperitoneally, but not orally, administered prior to the first immunization with OVA. The production of IL-4 and IFN-γ in response to OVA in spleen cells isolated from OVA-sensitized mice treated with fucoidan in vivo was lower than that from mice treated without fucoidan. Moreover, the flow cytometric analysis and ELISpot assay revealed that the administration of fucoidan suppressed a number of IgE-expressing and IgE-secreting B cells respectively. These results indicate that fucoidan inhibits the increase of plasma IgE through the suppression of IgE-producing B cell population, and the effect of fucoidan in vivo is crucially dependent on the route and timing of its administration.
Introduction
Elevated serum levels of specific IgE towards common environmental allergens characterize allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis [1, 2] . IgE plays a critical role in type I hypersensitivity reactions, binding to the high-affinity IgE receptor (FcεRI) on mast cells via the Cε3 domain on its Fc fragment. The cross-linking of IgE on mast cells by specific antigens results in the release of inflammatory mediators, such as histamine, enzymes, and cytokines [3] . These factors cause the immediate hypersensitivity reactions, and the late-phase inflammatory reaction involving T cells and eosinophils [4] .
Recent studies have shown that the ligation of IgE itself on FcεRI without antigen can cause the release of such inflammatory mediators, morphological changes, such as membrane ruffling, and migration of mast cells [5, 6] . Moreover, it is reported that recombinant humanized anti-IgE, which rapidly reduces serum free IgE concentrations and down-regulates IgE receptors, alleviates symptom of allergic diseases [7, 8] . Therefore, the control of IgE production is an important target for both prevention and treatment of atopic diseases.
Fucoidan, a dietary fiber purified from seaweed, is composed of a polymer of α1→3-linked L-fucose with sulfate groups on some of the fucose residents at the 4 position. It is reported that fucoidan may modulate the function of immune cells including macrophages, natural killer (NK) cells, lymphocytes and neutrophils [9, 10] . However, only few studies of 4 fucoidan have been conducted concerning the effect on allergy. We previously reported that fucoidan inhibits IgE production from B cells derived from mouse spleen by preventing NF-κB p52-mediated pathways in vitro [11] .
In this study, we investigated the effects of fucoidan on the increase of plasma IgE and the population of IgE-producing and -secreting B cells in ovalbumin (OVA)-sensitized mice in vivo, and the release of IL-4 and IFN-γ from T-cells in vitro.
Materials and methods

Animals:
Female Balb/c (4 weeks) mice were purchased from Charles River Japan (Yokohama, Japan). They were maintained in a specific pathogen-free environment in closed racks with free access to food and water in the Institute of Laboratory Animal Science, Hiroshima University. This study was carried out in accordance with the Guidelines for Animal Experiments for Laboratory Animal Science, Natural Science Center for Basic Research and Development (N-BARD), Hiroshima University.
Preparation and culture of spleen cells: Spleens were isolated from mice and minced in RPMI 1640 medium (Invitrogen) with 10% fetal calf serum and antibiotics. Lymphocyte suspensions (spleen cells) were obtained with a nylon mesh filter (BD Biosciences, Franklin 5 Lakes, NJ) and a density separation medium (Lympholyte-M; Cedarlane Laboratories, Hornby, Canada). The isolated spleen cells were distributed onto a 96-well tissue plate and maintained for 3 days at 37℃ in an atmosphere containing 5% CO 2 in the presence of 1 mg/ml OVA with or without fucoidan.
Ovalbumin immunization and administration of fucoidan:
Mice were immunized intraperitoneally with OVA (2 μg/mouse) (Sigma) with an alum adjuvant (LSL, Tokyo, Japan).
Two, four and six weeks after the first immunization, the mice were given boosters using the same doses of the antigen. From 1 week before the first immunization or indicated time points, mice were administered with fucoidan either orally (10 mg/mouse) or intraperitoneally (100 μg/mouse) 3 times every week. One week after every antigen challenge, plasma was obtained by retro-orbital bleeding. Blood from each mouse was placed in a heparinized plastic tube and centrifuged at 10,000 g for 10 min. After centrifugation, plasma was collected and stored at -80℃ for analysis.
Measurement of IgE, IgG1,IgG2a, IL-4, and IFN-γ in plasma:
The concentrations of IgE, IL-4 and IFN-γ in plasma were determined by means of mouse IgE ELISA kit purchased from Bethyl Laboratories (Montgomery, TX), mouse OVA-specific IgE ELISA kit purchased 6 from Shibayagi (Gunma, Japan), mouse IL-4 ELISA kit purchased from BD Biosciences, or mouse IFN-γ ELISA kit purchased from R&D systems, following the manufacturers' instructions, respectively. The concentrations of total IgG1 [12] , OVA-specific IgG1 [13] , total IgG2a [12] , OVA-specific IgG2a [12] were determined by sandwich ELISA as described previously. 
Results
Effects of fucoidan on the increase of plasma IgE levels in OVA-sensitized mice in vivo
We administered fucoidan either orally or intraperitoneally, to mice being sensitized with OVA, and examined the increase of plasma IgE. As shown in Fig. 1, intraperitoneal injections, but not oral treatments, of fucoidan to OVA-sensitized mice effectively prevented the increase of plasma IgE levels.
Timing of fucoidan administration to mice in the course of OVA-sensitisation
To determine optimal timing of administration for fucoidan to suppress the increase of plasma IgE by OVA sensitization, we commenced administration of fucoidan at several time points; 1 week before (group A), 1 day before (group B), at the same time as (group C), or 1 week after the first immunization with OVA (group D). Group E was immunized with OVA, but not treated with fucodian. Group F was treated neither with OVA nor fucoidan. As shown in Fig.   2a and b, total IgE levels in plasma of OVA-sensitized mice were significantly suppressed by 8 repetitive injections of fucoidan that were started before the immunization with OVA (group A and B). However, only a small effect of fucoidan was observed when injections were started at the same time as, or after the immunization with OVA (group C and D). OVA-specific IgE levels in plasma of OVA-sensitized mice were also significantly suppressed by repetitive injections of fucoidan started before the first immunization with OVA as well (group A and B) (Fig. 2c) . Both total and OVA-specific IgG1 levels in plasma of OVA-sensitized mice were also suppressed by fucoidan (Supplementary figure. 1a), whereas both total and OVA-specific IgG2a levels tended to be higher in mice treated with fucoidan (Supplementary figure. 1b) .
Effects of fucoidan on the release of IL-4 and IFN-γ from spleen cells isolated from
OVA-sensitized mice
It is well established that IL-4 and IFN-γ play critical roles in the regulation of IgE levels in plasma. We therefore investigated the effects of fucoidan on the release of cytokines from spleen cells in response to OVA. Spleen cells isolated from OVA-sensitized mice without treatment with fucoidan in vivo, were stimulated by 1 mg/ml OVA for 3 days in the presence or absence of 100 μg /ml fucoidan in vitro. As shown in Fig.3a , the release of IL-4 and IFN-γ in response to OVA from spleen cells, which were isolated from mice sensitized with OVA in vivo,
was not affected by the presence of fucoidan in vitro.
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Next we investigated the effect of injection with fucoidan on the release of cytokines in vitro in response to OVA. As shown in Fig. 3b , the release of IL-4 and IFN-γ in response to OVA from spleen cells, which were isolated from OVA-sensitized mice injected with fucoidan in vivo, was lower than that from mice sensitized with OVA without injections of fucoidan.
Effects of fucoidan on the population of IgE-producing B cells in OVA-sensitized mice
To persons, who ate 300 mg fucoidan over a period of 12 days [15] . This result indicated that more than 0.5% of orally administered fucoidan was transferred to the blood, suggesting that oral treatment with 10 mg fucoidan per mouse with 2 ml blood circulation conveys 25 μg/ml fucoidan into the plasma, which is enough to suppress the activation of B cells. Another possibility is that fucoidan may be digested into an inactive form in gastrointestinal tract.
Further study of plasma concentrations of fucoidan and its biological activities are necessary to evaluate the usability of oral administration of fucoidan.
In conclusion, fucoidan may suppress the increase of plasma IgE level in response to OVA injections, through the inhibition of IgE production and class switching in B cells in vivo.
Further studies of molecular actions of fucoidan may allow us to use fucoidan as a valuable 12 supplement or medicine for the prevention of IgE-mediated allergy. OVA-sensitized mice received fucoidan either by intraperitoneal injections or oral treatments.
Figure legends
The administrations of fucoidan were started 1 week before the first immunization with OVA.
The levels of serum IgE were determined as described in the Materials and Methods section.
Data are means ± SEM (n=4) in one representative experiment. Similar results were obtained by three independent experiments. The difference among groups at each time points were tested using a one-way ANOVA followed by Dunnett's test and considered significant with P<0.01(**). obtained by three independent experiments. Differences among groups at each time points were tested using a one-way ANOVA followed by Dunnett's test and considered significant with P<0.01(**). ND: not detected. OVA specific IgG2a in plasma of mice 7 weeks after the first immunization with OVA. Data are means ± SEM (n=6). Differences among groups at each time points were tested using a one-way ANOVA followed by Dunnett's test and considered significant with P<0.05(*) and P<0.01(**).
ND: not detected. 
